Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129


Erratum. Genetics coming of age in type 1 diabetes. Diabetes Care 2019;42:189-191.

Cerosaletti K, Hao W, Greenbaum CJ.

Diabetes Care. 2019 Mar 18. pii: dc19er05. doi: 10.2337/dc19-er05. [Epub ahead of print] No abstract available.


B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.

Linsley PS, Greenbaum CJ, Speake C, Long SA, Dufort MJ.

JCI Insight. 2019 Feb 21;4(4). pii: 126136. doi: 10.1172/jci.insight.126136. eCollection 2019 Feb 21.


Cell type-specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes.

Dufort MJ, Greenbaum CJ, Speake C, Linsley PS.

JCI Insight. 2019 Feb 21;4(4). pii: 125556. doi: 10.1172/jci.insight.125556. eCollection 2019 Feb 21.


Genetics Coming of Age in Type 1 Diabetes.

Cerolsaletti K, Hao W, Greenbaum CJ.

Diabetes Care. 2019 Feb;42(2):189-191. doi: 10.2337/dci18-0039. No abstract available. Erratum in: Diabetes Care. 2019 Mar 18;:.


Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.

Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC; Immune Tolerance Network.

Diabetologia. 2019 Apr;62(4):655-664. doi: 10.1007/s00125-018-4786-9. Epub 2018 Dec 19.


Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes.

Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J, Mastracci TL, Marcovina S, Qian WJ, Yi L, Swensen AC, Yip-Schneider M, Schmidt CM, Considine RV, Arvan P, Greenbaum CJ, Evans-Molina C; T1D Exchange Residual C-peptide Study Group.

Diabetes Care. 2019 Feb;42(2):258-264. doi: 10.2337/dc17-2625. Epub 2018 Dec 10.


DRB4*01:01 Has a Distinct Motif and Presents a Proinsulin Epitope That Is Recognized in Subjects with Type 1 Diabetes.

James EA, Gillette L, Durinovic-Bello I, Speake C, Bondinas GP, Moustakas AK, Greenbaum CJ, Papadopoulos GK, Kwok WW.

J Immunol. 2018 Dec 15;201(12):3524-3533. doi: 10.4049/jimmunol.1800723. Epub 2018 Nov 19.


First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes.

Cousminer DL, Ahlqvist E, Mishra R, Andersen MK, Chesi A, Hawa MI, Davis A, Hodge KM, Bradfield JP, Zhou K, Guy VC, Åkerlund M, Wod M, Fritsche LG, Vestergaard H, Snyder J, Højlund K, Linneberg A, Käräjämäki A, Brandslund I, Kim CE, Witte D, Sørgjerd EP, Brillon DJ, Pedersen O, Beck-Nielsen H, Grarup N, Pratley RE, Rickels MR, Vella A, Ovalle F, Melander O, Harris RI, Varvel S, Grill VER; Bone Mineral Density in Childhood Study, Hakonarson H, Froguel P, Lonsdale JT, Mauricio D, Schloot NC, Khunti K, Greenbaum CJ, Åsvold BO, Yderstræde KB, Pearson ER, Schwartz S, Voight BF, Hansen T, Tuomi T, Boehm BO, Groop L, Leslie RD, Grant SFA.

Diabetes Care. 2018 Nov;41(11):2396-2403. doi: 10.2337/dc18-1032. Epub 2018 Sep 25.


Innate immune activity as a predictor of persistent insulin secretion and association with responsiveness to CTLA4-Ig treatment in recent-onset type 1 diabetes.

Cabrera SM, Engle S, Kaldunski M, Jia S, Geoffrey R, Simpson P, Szabo A, Speake C, Greenbaum CJ; Type 1 Diabetes TrialNet CTLA4-Ig (Abatacept) Study Group, Chen YG, Hessner MJ.

Diabetologia. 2018 Nov;61(11):2356-2370. doi: 10.1007/s00125-018-4708-x. Epub 2018 Aug 30.


ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents.

Couper JJ, Haller MJ, Greenbaum CJ, Ziegler AG, Wherrett DK, Knip M, Craig ME.

Pediatr Diabetes. 2018 Oct;19 Suppl 27:20-27. doi: 10.1111/pedi.12734. No abstract available.


Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.

Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group.

Diabetes Care. 2018 Sep;41(9):1917-1925. doi: 10.2337/dc18-0494. Epub 2018 Jul 16.


Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes.

Linsley PS, Greenbaum CJ, Rosasco M, Presnell S, Herold KC, Dufort MJ.

Genes Immun. 2018 Jun 21. doi: 10.1038/s41435-018-0032-1. [Epub ahead of print]


Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience.

Greenbaum CJ, Speake C, Krischer J, Buckner J, Gottlieb PA, Schatz DA, Herold KC, Atkinson MA.

Diabetes. 2018 Jul;67(7):1216-1225. doi: 10.2337/db18-0065. Epub 2018 May 16.


Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4+ T Cells in Patients With Type 1 Diabetes.

Marre ML, McGinty JW, Chow IT, DeNicola ME, Beck NW, Kent SC, Powers AC, Bottino R, Harlan DM, Greenbaum CJ, Kwok WW, Piganelli JD, James EA.

Diabetes. 2018 Jul;67(7):1356-1368. doi: 10.2337/db17-1166. Epub 2018 Apr 13.


Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes.

Bingley PJ, Wherrett DK, Shultz A, Rafkin LE, Atkinson MA, Greenbaum CJ.

Diabetes Care. 2018 Apr;41(4):653-661. doi: 10.2337/dc17-0806.


Erratum. Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785-1787.

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2018 Apr;41(4):913. doi: 10.2337/dc18-er04a. Epub 2018 Feb 23. No abstract available.


Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.

Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ.

JAMA. 2017 Nov 21;318(19):1891-1902. doi: 10.1001/jama.2017.17070.


Stacking the Deck: Studies of Patients with Multiple Autoimmune Diseases Propelled Our Understanding of Type 1 Diabetes as an Autoimmune Disease.

Buckner JH, Greenbaum CJ.

J Immunol. 2017 Nov 1;199(9):3011-3013. doi: 10.4049/jimmunol.1701299. No abstract available.


Assessment of β Cell Mass and Function by AIRmax and Intravenous Glucose in High-Risk Subjects for Type 1 Diabetes.

Hao W, Woodwyk A, Beam C, Bahnson HT, Palmer JP, Greenbaum CJ.

J Clin Endocrinol Metab. 2017 Dec 1;102(12):4428-4434. doi: 10.1210/jc.2017-01713. Erratum in: J Clin Endocrinol Metab. 2018 Apr 1;103(4):1653.


Erratum to: Understanding and preventing type 1 diabetes through the unique working model of TrialNet.

Battaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH, Lernmark Å, Muller S, Pugliese A, Roep BO, Greenbaum CJ, Peakman M.

Diabetologia. 2017 Dec;60(12):2540. doi: 10.1007/s00125-017-4446-5. No abstract available.


Understanding and preventing type 1 diabetes through the unique working model of TrialNet.

Battaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH, Lernmark Å, Muller S, Pugliese A, Roep BO, Greenbaum CJ, Peakman M.

Diabetologia. 2017 Nov;60(11):2139-2147. doi: 10.1007/s00125-017-4384-2. Epub 2017 Aug 2. Review. Erratum in: Diabetologia. 2017 Sep 26;:.


Single-Cell RNA Sequencing Reveals Expanded Clones of Islet Antigen-Reactive CD4+ T Cells in Peripheral Blood of Subjects with Type 1 Diabetes.

Cerosaletti K, Barahmand-Pour-Whitman F, Yang J, DeBerg HA, Dufort MJ, Murray SA, Israelsson E, Speake C, Gersuk VH, Eddy JA, Reijonen H, Greenbaum CJ, Kwok WW, Wambre E, Prlic M, Gottardo R, Nepom GT, Linsley PS.

J Immunol. 2017 Jul 1;199(1):323-335. doi: 10.4049/jimmunol.1700172. Epub 2017 May 31.


Antigen-Specific T Cell Analysis Reveals That Active Immune Responses to β Cell Antigens Are Focused on a Unique Set of Epitopes.

Yang J, Wen X, Xu H, Torres-Chinn N, Speake C, Greenbaum CJ, Nepom GT, Kwok WW.

J Immunol. 2017 Jul 1;199(1):91-96. doi: 10.4049/jimmunol.1601570. Epub 2017 May 26.


Measurement of Pro-Islet Amyloid Polypeptide (1-48) in Diabetes and Islet Transplants.

Courtade JA, Klimek-Abercrombie AM, Chen YC, Patel N, Lu PYT, Speake C, Orban PC, Najafian B, Meneilly G, Greenbaum CJ, Warnock GL, Panagiotopoulos C, Verchere CB.

J Clin Endocrinol Metab. 2017 Jul 1;102(7):2595-2603. doi: 10.1210/jc.2016-2773.


Longitudinal monitoring of gene expression in ultra-low-volume blood samples self-collected at home.

Speake C, Whalen E, Gersuk VH, Chaussabel D, Odegard JM, Greenbaum CJ.

Clin Exp Immunol. 2017 May;188(2):226-233. doi: 10.1111/cei.12916. Epub 2017 Mar 2.


Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression.

Hundhausen C, Roth A, Whalen E, Chen J, Schneider A, Long SA, Wei S, Rawlings R, Kinsman M, Evanko SP, Wight TN, Greenbaum CJ, Cerosaletti K, Buckner JH.

Sci Transl Med. 2016 Sep 14;8(356):356ra119. doi: 10.1126/scitranslmed.aad9943.


Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose.

Hao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2016 Oct;39(10):1664-70. doi: 10.2337/dc16-0360. Epub 2016 Jul 15.


The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants.

Meah FA, DiMeglio LA, Greenbaum CJ, Blum JS, Sosenko JM, Pugliese A, Geyer S, Xu P, Evans-Molina C; Type 1 Diabetes TrialNet Study Group.

Diabetologia. 2016 Jun;59(6):1186-95. doi: 10.1007/s00125-016-3924-5. Epub 2016 Mar 19.


Identification of tissue-specific cell death using methylation patterns of circulating DNA.

Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-Dembinsky A, Rubertsson S, Nellgård B, Blennow K, Zetterberg H, Spalding K, Haller MJ, Wasserfall CH, Schatz DA, Greenbaum CJ, Dorrell C, Grompe M, Zick A, Hubert A, Maoz M, Fendrich V, Bartsch DK, Golan T, Ben Sasson SA, Zamir G, Razin A, Cedar H, Shapiro AM, Glaser B, Shemer R, Dor Y.

Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1826-34. doi: 10.1073/pnas.1519286113. Epub 2016 Mar 14.


NETosis-associated serum biomarkers are reduced in type 1 diabetes in association with neutrophil count.

Qin J, Fu S, Speake C, Greenbaum CJ, Odegard JM.

Clin Exp Immunol. 2016 Jun;184(3):318-22. doi: 10.1111/cei.12783. Epub 2016 Apr 13.


Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.

Cabrera SM, Wang X, Chen YG, Jia S, Kaldunski ML, Greenbaum CJ; Type 1 Diabetes TrialNet Canakinumab Study Group, Mandrup-Poulsen T; AIDA Study Group, Hessner MJ.

Eur J Immunol. 2016 Apr;46(4):1030-46. doi: 10.1002/eji.201546005. Epub 2016 Jan 21.


Changing the Course of Disease in Type 1 Diabetes.

VanBuecken D, Lord S, Greenbaum CJ.

In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA):, Inc.; 2000-.
2018 Jun 11.


Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.

Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2015 Oct;38(10):1975-85. doi: 10.2337/dc15-1429. Review.


Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.

Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG.

Diabetes Care. 2015 Oct;38(10):1964-74. doi: 10.2337/dc15-1419. Review.


Stress Testing of an Artificial Pancreas System With Pizza and Exercise Leads to Improvements in the System's Fuzzy Logic Controller.

Mauseth R, Lord SM, Hirsch IB, Kircher RC, Matheson DP, Greenbaum CJ.

J Diabetes Sci Technol. 2015 Sep 14;9(6):1253-9. doi: 10.1177/1932296815602098.


Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.

Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR.

J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20.


Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?

Lord S, Greenbaum CJ.

Pharmacol Res. 2015 Aug;98:3-8. doi: 10.1016/j.phrs.2015.02.002. Epub 2015 Mar 11. Review.


The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10.


The Effect of DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and Postprandial Glucose Tolerance.

Hao W, Greenbaum CJ, Krischer JP, Cuthbertson D, Marks JB, Palmer JP.

Diabetes Care. 2015 May;38(5):891-6. doi: 10.2337/dc14-1825. Epub 2015 Feb 26.


Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective.

Bollyky JB, Xu P, Butte AJ, Wilson DM, Beam CA, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

Diabetes Metab Res Rev. 2015 Sep;31(6):588-94. doi: 10.1002/dmrr.2643. Epub 2015 Apr 23.


A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history.

Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2015 Feb;38(2):271-6. doi: 10.2337/dc14-1813. Epub 2014 Dec 17.


Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes.

Davis AK, DuBose SN, Haller MJ, Miller KM, DiMeglio LA, Bethin KE, Goland RS, Greenberg EM, Liljenquist DR, Ahmann AJ, Marcovina SM, Peters AL, Beck RW, Greenbaum CJ; T1D Exchange Clinic Network.

Diabetes Care. 2015 Mar;38(3):476-81. doi: 10.2337/dc14-1952. Epub 2014 Dec 17.


Autoreactive T cells specific for insulin B:11-23 recognize a low-affinity peptide register in human subjects with autoimmune diabetes.

Yang J, Chow IT, Sosinowski T, Torres-Chinn N, Greenbaum CJ, James EA, Kappler JW, Davidson HW, Kwok WW.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14840-5. doi: 10.1073/pnas.1416864111. Epub 2014 Sep 29.


Avidity-dependent programming of autoreactive T cells in T1D.

Durinovic-Belló I, Gersuk VH, Ni C, Wu R, Thorpe J, Jospe N, Sanda S, Greenbaum CJ, Nepom GT.

PLoS One. 2014 May 20;9(5):e98074. doi: 10.1371/journal.pone.0098074. eCollection 2014.


Molecular signatures differentiate immune states in type 1 diabetic families.

Chen YG, Cabrera SM, Jia S, Kaldunski ML, Kramer J, Cheong S, Geoffrey R, Roethle MF, Woodliff JE, Greenbaum CJ, Wang X, Hessner MJ.

Diabetes. 2014 Nov;63(11):3960-73. doi: 10.2337/db14-0214. Epub 2014 Apr 23.


Residual C-peptide in type 1 diabetes: what do we really know?

VanBuecken DE, Greenbaum CJ.

Pediatr Diabetes. 2014 Mar;15(2):84-90. doi: 10.1111/pedi.12135. Review.


Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.

Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team.

Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23.


Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes.

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups.

Diabetes Care. 2014 Apr;37(4):979-84. doi: 10.2337/dc13-2359. Epub 2014 Feb 18.


Low HERV-K(C4) copy number is associated with type 1 diabetes.

Mason MJ, Speake C, Gersuk VH, Nguyen QA, O'Brien KK, Odegard JM, Buckner JH, Greenbaum CJ, Chaussabel D, Nepom GT.

Diabetes. 2014 May;63(5):1789-95. doi: 10.2337/db13-1382. Epub 2014 Jan 15.


Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.

Orban T, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Russell WE, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Abatacept Study Group.

Diabetes Care. 2014 Apr;37(4):1069-75. doi: 10.2337/dc13-0604. Epub 2013 Dec 2.

Supplemental Content

Loading ...
Support Center